Studying Gene Expression in Samples From Patients With Rhabdoid Tumors
NCT ID: NCT01553175
Last Updated: 2016-07-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
25 participants
OBSERVATIONAL
2012-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research trial studies gene expression in samples from patients with rhabdoid tumors.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Biomarkers in Samples From Young Patients With Rhabdoid Tumors
NCT01544569
Studying Genes in Samples From Younger Patients With Rhabdomyosarcoma
NCT01585376
Biomarkers in Tumor Samples From Younger Patients With Neuroblastoma
NCT01493830
Studying Gene Expression in Samples From Younger Patients With Neuroblastoma
NCT01553448
Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor
NCT01453465
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine if BRM is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
* To determine if BRG1 is silenced in the majority, if not all, rhabdoid tumors by immunohistochemistry in primary tumors.
* To determine if GATA1 and/or HDAC2 is overexpressed in the same tumors that lack BRM expression.
* To determine if BRM promoter polymorphisms correlate with loss of BRM expression in primary rhabdoid tumors.
* To determine how BRG1 is silenced in primary rhabdoid tumors by sequencing BRG1 exons in genomic DNA derived from frozen samples.
OUTLINE: Archived tumor tissue samples are analyzed for BRM, BRG1, GATA1, and/or HDAC2 expression by immunohistochemistry. BRM- and BRG1-negative samples are also analyzed.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DNA analysis
gene expression analysis
mutation analysis
protein expression analysis
immunohistochemistry staining method
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Tumor samples from patients diagnosed with rhabdoid tumors
* Matched frozen tumor tissue from BRG1-negative tumors (preferred) or matched genomic DNA from tumors, 100 ng per tumor from BRG1-negative tumors
* Any source of DNA from BRG1-negative tumors (tumors, blood, etc.)
* Matched frozen tumor tissue from BRM-negative tumors to confirm that BRM is not mutated or altered but rather epigenetically suppressed when lost in rhabdoid tumors
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
120 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David Reisman, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Florida
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AREN12B5
Identifier Type: OTHER
Identifier Source: secondary_id
CDR0000728521
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2012-00705
Identifier Type: REGISTRY
Identifier Source: secondary_id
AREN12B5
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.